Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes

NAActive, not recruitingINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

April 1, 2026

Conditions

CancerGenetic Predisposition

Interventions

BEHAVIORAL

MyCancerGene

Interactive Health Communication Application

Trial Locations (1)

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

All Listed Sponsors

collaborator

American Cancer Society, Inc.

OTHER

lead

Abramson Cancer Center at Penn Medicine

OTHER